Cimepilimab price per injection and treatment cost

Cemiplimab (Cemiplimab) is a humanized IgG4 monoclonal antibody, a PD-1 immune checkpoint inhibitor, mainly used to treat certain types of advanced skin cancer, especially locally advanced or metastatic cutaneous squamous cell carcinoma and basal cell carcinoma (BCC), and some types of non-small cell lung cancer (NSCLC). This drug blocks the binding of PD-1 receptor and its ligand PD-L1/PD-L2, thereby lifting the immune suppression of T cells and enhancing the body's immune attack ability against tumor cells. The efficacy of cimepilimab has been verified in a number of key clinical trials, showing that it can bring durable remission and prolong survival in some patients, especially for patients who are incompatible or ineffective with traditional radiotherapy or chemotherapy.

Currently, cimepilimab has not been marketed in mainland China, and therefore has not been included in the medical insurance reimbursement list. The original drug cannot be legally obtained in domestic medical institutions, and the drug can only be used through overseas medical channels or imported at one's own expense. In the European and American markets, the common dosage form of cimepilimab is 350mg/7mL, and the price per bottle is approximately RMB 40,000 to RMB 100,000. The specific selling price is affected by factors such as version (US version or European version), channel source, and exchange rate fluctuations. In addition, cimepilimab is usually administered as an intravenous infusion of 350 mg every three weeks. The specific length of treatment depends on the patient's response to treatment and clinical condition, and usually lasts from several months to more than a year.

Because the drug is expensive, the total cost of a complete course of treatment may be hundreds of thousands of yuan or more, placing a heavy financial burden on patients. There is currently no generic drug version available globally, so the price lacks a basis for competition. For patients in need of medication, it is recommended to evaluate their risk-benefit ratio under the guidance of professional doctors, and seek overseas medical assistance or clinical trial participation opportunities if necessary. In the future, if cimepilimab is successfully approved for marketing in China and included in medical insurance, the related costs are expected to be significantly reduced.

Reference materials:https://www.libtayohcp.com/